3.90Open4.15Pre Close828 Volume1.37K Open Interest17.50Strike Price353.88KTurnover435.49%IV35.31%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier11DDays to Expiry4.00Extrinsic Value100Contract SizeAmericanOptions Type-0.2705Delta0.0212Gamma5.15Leverage Ratio-0.2449Theta-0.0027Rho-1.39Eff Leverage0.0119Vega
Jasper Therapeutics Stock Discussion
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
14 of 15 participants enrolled achieved a clinical response
10 of 12 participants in the 120mg cohort achieved a complete response
No serious adverse events; no grade 3 or higher adverse events reported
Initial data from BEACON study expected week of January 6th, 2025, including 180mg Q8W cohort
Company to host conference call and webinar today at 8:00 ...
Microsoft $Microsoft (MSFT.US)$ (office currently has nearly 400 million users, OficARPU increases after the acquisition of OpenA and Azurez-related...
No comment yet